Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma announced positive topline results from its Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients. The study met its primary safety endpoint with ATYR1923 being well-tolerated at doses of 1.0 and 3.0 mg/kg. Notably, patients receiving the 3.0 mg/kg dose demonstrated a median recovery time of 5.5 days, and 83% recovered in less than a week. The trial involved 32 patients and assessed safety and preliminary efficacy against a placebo. The company plans to provide further insights during a conference call on January 4.
aTyr Pharma (Nasdaq: LIFE) has announced the completion of target enrollment in its Phase 1b/2a clinical trial for ATYR1923, aimed at treating pulmonary sarcoidosis, with 36 patients enrolled. Results are anticipated in Q3 2021, potentially guiding future studies in interstitial lung diseases (ILD). ATYR1923 targets immune modulation to improve lung function with reduced toxicity compared to existing treatments. Additionally, a Phase 2 trial for COVID-19 patients has completed enrollment, with topline data expected soon.
aTyr Pharma has completed enrollment in its Phase 2 trial of ATYR1923 for COVID-19 patients, expecting topline data soon. The company is advancing its oncology pipeline with the new candidate ATYR2810 and has ongoing collaborations for research development. Financially, aTyr reported revenues of $0.1 million for Q3 2020, compared to $0.2 million in Q3 2019. R&D expenses rose to $4.6 million, reflecting increased clinical activities. As of September 30, 2020, cash and investments totaled $36.1 million, following the repayment of $3.1 million in loans.
On November 11, 2020, aTyr Pharma (Nasdaq: LIFE) announced a publication of a peer-reviewed paper demonstrating advancements in its antibody program. The research, conducted in collaboration with AbCellera Biologics, highlights methods for isolating and engineering human antibodies with high target affinity. Utilizing its tRNA synthetase biology platform, aTyr aims to create new biologics to modulate therapeutic pathways. The findings have already contributed to the development of antibody candidates for targeting Neuropilin-2, enhancing aTyr's pipeline for future therapeutic applications.
aTyr Pharma (Nasdaq: LIFE) has identified receptor targets for two tRNA synthetases, paving the way for new therapies targeting cancer and fibrosis. This discovery is significant as it enhances understanding of extracellular tRNA synthetases' roles in disease and informs future drug development. The findings were achieved through collaboration with CSL Behring. CEO Sanjay Shukla highlighted this as a major milestone in their drug discovery efforts.
aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, is set to report its third quarter 2020 financial results and provide a corporate update on November 12, 2020, after market close. The company is focused on the discovery and development of innovative medicines utilizing novel biological pathways, particularly through its lead product candidate, ATYR1923, aimed at treating inflammatory lung diseases. A conference call and webcast will take place on the same day at 5:00 p.m. EST.
aTyr Pharma announced a research collaboration with the Medical University of South Carolina to advance its neuropilin-2 (NRP2) antibody program in oncology. Led by Dr. Robert Gemmill, the collaboration seeks to develop therapeutic antibodies targeting specific NRP2 isoforms, particularly in lung cancer, which is characterized by high NRP2 expression correlating with poor outcomes. aTyr aims to leverage this partnership to enhance therapeutic strategies against lung cancer, addressing a significant medical need amid rising drug resistance in aggressive cases.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will participate in a panel discussion titled, “Immune Modulators to Ameliorate COVID-19” during the ROTH Capital Partners Webinar on October 28, 2020. This webinar will focus on COVID-19 therapeutics in development and aims to explore innovative treatments.
The event is scheduled from 9:00 a.m. to 10:20 a.m. Eastern Time. Registration is available on aTyr's website, and a replay will follow.
aTyr Pharma, Inc. (Nasdaq: LIFE) has successfully completed enrollment in its Phase 2 clinical trial of ATYR1923, targeting COVID-19 patients with severe respiratory complications. The trial enrolled 32 patients, surpassing the initial goal of 30. Results are anticipated by the fourth quarter of 2020. ATYR1923 aims to address excessive inflammatory responses in the lungs, offering a potential treatment where few options exist. The study is a double-blind, placebo-controlled trial, evaluating safety and efficacy through key clinical outcomes over a 60-day follow-up period.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) announced participation in two virtual investor events this October. CEO Sanjay S. Shukla will engage in a Q&A webinar on October 12 at 12:00pm ET, part of the ROTH Capital Partners’ CEO Talk Series. CFO Jill M. Broadfoot will present a corporate overview at the BIO Investor Forum Digital from October 13-15. aTyr focuses on developing innovative medicines based on tRNA synthetases, particularly its clinical-stage candidate ATYR1923 for inflammatory lung diseases.